ASTA Statement on FDA Plant and Animal Biotechnology Innovation Action Plan

  • On October 31, 2018

Alexandria, Va.—October 31, 2018–The following is a statement from American Seed Trade Association (ASTA) President & CEO Andrew LaVigne regarding the U.S. Food and Drug Administration’s (FDA) new Action Plan on biotechnology innovation:

“We’re encouraged by FDA’s announcement that the agency is moving forward on a plan to provide clarity and foster future innovation around evolving plant breeding methods.

“ASTA submitted detailed comments on this topic to FDA in June. As the agency progresses in its efforts to complete this process, we look forward to continuing to provide important input and expertise on behalf of the U.S. seed industry. America’s plant breeding community has an excellent record of bringing new plant varieties to the marketplace for the benefit of farmers, gardeners, consumers and others, and we plan to continue that record as plant breeding methods evolve. 

“To ensure U.S. agriculture remains at the forefront of innovation and maintains its leadership role globally, it’s critical that we have clear, consistent and science-based federal policies around new and emerging plant breeding methods.”


Founded in 1883, the American Seed Trade Association (ASTA) represents over 700 companies involved in seed production, plant breeding and related industries in North America. ASTA is the leading voice of action in all matters concerning the development, marketing and movement of seed, associated products and services throughout the world. The association’s broad membership offers varieties from alfalfa to zucchini and all production types including conventional, organic and biotech. ASTA promotes the development of better seed to produce better crops for a better quality of life.